Ainos enters $10M private placement with Lind Global; initial $3M tranche funded

Ainos, Inc.

Initial closing: $2M funded now; remaining $1M subject to shareholder approval and SEC registration.
Senior secured convertible note (18-month maturity) convertible at $1.50/share; warrants at $0.90/share.
Proceeds to fund clinical trials, commercial product launch, and working capital.
Additional tranches up to $7M possible upon mutual agreement and satisfaction of conditions.
Maxim Group and Brookline Capital Markets acted as placement agents.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Ainos, Inc. entered into Securities Purchase Agreement with Lind Global Fund II LP valued at up to $10 million (effective 2023-09-25).

Action: entry
Agreement: equity purchase
Counterparty: Lind Global Fund II LP
Value: up to $10 million
Effective: 2023-09-25

Exact text from the filing

On September 25, 2023, AINOS, INC. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Lind Global Fund II LP (“Lind”). The Securities Purchase Agreement provides for loans in an aggregate principal amount of up to $10 million under various tranches (the “Financing”).

View on SEC.gov

Browse all material agreements →

Ainos, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-012402

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.